Brief introduction of N1,N2-Di-tert-butylethane-1,2-diamine

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Application of 4062-60-6, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 4062-60-6, in my other articles.

Application of 4062-60-6, Catalysts are substances that increase the reaction rate of a chemical reaction without being consumed in the process. 4062-60-6, Name is N1,N2-Di-tert-butylethane-1,2-diamine, molecular formula is C10H24N2. In a Article，once mentioned of 4062-60-6

Liver X receptor (LXR) agonists are candidates for the treatment of atherosclerosis via induction of ABCA1 (ATP-binding cassette A1) gene expression, which contributes to reverse cholesterol transport (RCT) and to cholesterol efflux from the liver and intestine. However, LXR agonists also induce genes involved in lipogenesis, such as SREBP-1c (sterol regulatory binding element protein 1c) and FAS (fatty acid synthase), thereby causing an undesirable increase in plasma and hepatic triglyceride (TG) levels. Recent studies indicate that LXRalpha contributes to lipogenesis in liver, and selective LXRbeta activation improves RCT in mice. Therefore, LXRbeta-selective agonists are promising candidates to improve atherosclerosis without increasing plasma or hepatic TG levels. However, the ligand-binding domains in the two LXR isoforms alpha/beta share high sequence identity, and few LXR ligands show subtype selectivity. In this study we identified a tetrachlorophthalimide analogue as an LXRbeta-selective agonist. Structural development led to (E)-4,5,6,7-tetrachloro-2-(2-styrylphenyl)isoindoline-1,3-dione (24 a), which shows potent and selective LXRbeta agonistic activity in reporter gene assays. In binding assays, compound 24 a bound to LXRbeta preferentially over LXRalpha. It also induced the expression of ABCA1 mRNA but not SREBP-1c mRNA in cells. Compound 24 a appears to be a promising lead compound for therapeutic agents to treat atherosclerosis without the side effects induced by LXRalpha/beta dual agonists.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Application of 4062-60-6, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 4062-60-6, in my other articles.

Reference：
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI